When is it appropriate to initiate a JAK inhibitor for frontal fibrosing alopecia, and what are the recommended dosing, monitoring, and contraindications?

JAK Inhibitors for Frontal Fibrosing Alopecia

JAK inhibitors are not currently approved for frontal fibrosing alopecia (FFA), but emerging evidence suggests topical delgocitinib 2% cream may be considered as an off-label treatment option in recalcitrant cases after failure of conventional therapies, based on the only randomized controlled trial showing molecular and clinical improvements.

Current Evidence Base

The evidence for JAK inhibitors in FFA is extremely limited but promising. The highest quality study is a phase 2a randomized, double-blind trial of topical delgocitinib 2% cream versus vehicle in 30 adult females with FFA 1. This trial demonstrated:

• Significant downregulation of the T helper 1-related biomarker CXCL9 (-3.10; P < .05) at 12 weeks
• Small but significant improvement in transcriptomic profile (4%; P < .001) versus worsening with vehicle (33%)
• Good tolerability with improvements in exploratory clinical severity endpoints
• No serious adverse events

Additional evidence from retrospective cohorts suggests topical tofacitinib 2% and topical ruxolitinib 1.5% may also show benefit in scarring alopecia, though these are lower quality studies 2, 3.

When to Initiate JAK Inhibitors

Consider JAK inhibitors only after:

1. Failure of first-line therapies - Specifically after inadequate response to intralesional or systemic corticosteroids, hydroxychloroquine, or 5-alpha reductase inhibitors (finasteride/dutasteride)
2. Active, progressive disease - Documented hairline recession with positive trichoscopy findings (perifollicular erythema, follicular hyperkeratosis)
3. Significant impact on quality of life - Patient distress warranting escalation beyond conventional options

Do not initiate if:

• Disease appears stable/inactive (no progression over 6-12 months)
• Patient has contraindications to JAK inhibitors (see below)

Recommended Approach

Topical JAK Inhibitors (Preferred for FFA)

Delgocitinib 2% cream:

• Apply to affected areas twice daily
• Duration: Minimum 12 weeks to assess response
• Monitor for local irritation (most common side effect)

Alternative topical options (based on lower-quality evidence):

• Tofacitinib 2% ointment twice daily
• Ruxolitinib 1.5% cream twice daily

Systemic JAK Inhibitors (Reserve for Extensive/Refractory Cases)

If considering systemic therapy, follow established JAK inhibitor protocols from rheumatology/dermatology guidelines 4, 5:

Dosing options:

• Tofacitinib 5 mg twice daily
• Baricitinib 2-4 mg daily
• Upadacitinib 15 mg daily

Baseline Screening Requirements

Before initiating any JAK inhibitor 4, 5:

1. Laboratory testing:

   • Complete blood count with differential
   • Comprehensive metabolic panel (liver and renal function)
   • Lipid panel
   • Pregnancy test (women of childbearing potential)

2. Infectious disease screening:

   • Tuberculosis testing (QuantiFERON or PPD)
   • Hepatitis B serology (HBsAg, anti-HBc, anti-HBs)
   • Hepatitis C antibody
   • HIV testing (if risk factors present)

3. Vaccination status:

   • Herpes zoster vaccine (recombinant, non-live) is strongly recommended before starting therapy - particularly important given 3-4 fold increased risk of reactivation 4, 5
   • Update all other non-live vaccines as needed
   • Complete live vaccines at least 4 weeks before initiation

4. Baseline skin examination:

   • Document for non-melanoma skin cancer risk 4

Monitoring During Treatment

For Topical JAK Inhibitors:

• Clinical assessment every 3 months to evaluate hairline progression
• Trichoscopy at baseline and 6 months to assess inflammatory activity
• No routine laboratory monitoring required for topical formulations given minimal systemic absorption 1, 2

For Systemic JAK Inhibitors:

Laboratory monitoring schedule 4, 5:

• Weeks 4-12: CBC, liver enzymes, lipids
• Every 3 months thereafter: CBC, liver enzymes, renal function
• Annually: Lipid panel, skin examination

Hold or adjust dose if:

• Absolute neutrophil count 500-1000/mm³ (hold until >1000/mm³)
• Absolute lymphocyte count 500-750/mm³ (hold until >750/mm³)
• Hemoglobin decrease >20 g/L or <80 g/L (hold until normalized)
• ALT/AST >3x upper limit of normal (hold until <2x ULN)
• Creatinine clearance <30 mL/min (contraindicated for most agents)

Contraindications

Absolute contraindications 4:

1. Active serious infections (bacterial, viral, fungal, or opportunistic)
2. Active tuberculosis or untreated latent TB
3. Pregnancy or breastfeeding (teratogenic in animal studies)
4. Severe hepatic impairment (Child-Pugh C)
5. Severe renal impairment (CrCl <30 mL/min for most agents)
6. Active malignancy or recent malignancy (<5 years, except adequately treated non-melanoma skin cancer)

Relative contraindications requiring careful risk-benefit assessment 4, 5:

1. Age >65 years with cardiovascular risk factors - FDA warning based on increased serious infections and cardiovascular events with tofacitinib in RA patients
2. History of venous thromboembolism - increased VTE risk, especially pulmonary embolism
3. History of malignancy (>5 years ago) - shared decision-making required
4. Chronic viral infections (HBV, HCV, HIV) - requires specialist co-management
5. Moderate renal impairment (CrCl 30-60 mL/min) - dose reduction required for some agents

Drug Interactions

Dose adjustments required for systemic JAK inhibitors 4:

• CYP3A4 inhibitors (ketoconazole, clarithromycin): Reduce tofacitinib/upadacitinib dose by 50%
• CYP3A4 inducers (rifampicin): May require dose increase of tofacitinib/upadacitinib
• OAT3 inhibitors (probenecid): Reduce baricitinib to 2 mg daily

Duration and Discontinuation

• Minimum trial duration: 12 weeks to assess molecular/clinical response 1
• Optimal treatment duration: Unknown - no long-term data specific to FFA
• Consider discontinuation if:
  • No improvement in hairline progression by 6 months
  • Complete disease stabilization maintained for 12 months
  • Development of contraindications or intolerable side effects

Relapse is common after discontinuation - patients should be counseled that maintenance therapy may be required 6

Critical Safety Warnings

FDA boxed warnings for systemic JAK inhibitors 5:

1. Increased risk of serious cardiovascular events (MI, stroke) - particularly in patients >65 years with cardiovascular risk factors
2. Increased risk of malignancies including lymphoma and lung cancer
3. Increased risk of thrombosis (DVT, PE, arterial thrombosis)
4. Increased risk of death in high-risk populations

These warnings derive primarily from tofacitinib data in older RA patients with cardiovascular risk factors and may not fully apply to younger FFA patients, but warrant caution 5.

Common Pitfalls to Avoid

1. Using systemic JAK inhibitors as first-line therapy - Reserve for refractory cases given safety concerns
2. Inadequate infectious disease screening - TB reactivation and herpes zoster are real risks
3. Failing to vaccinate for herpes zoster before initiation - 3-4 fold increased reactivation risk
4. Insufficient monitoring - Cytopenias and lipid abnormalities require regular surveillance
5. Prescribing in elderly patients with cardiovascular risk factors without careful counseling - FDA restrictions apply
6. Expecting hair regrowth - Primary goal is disease stabilization/prevention of progression, not regrowth in scarred areas

Practical Algorithm

Step 1: Confirm active FFA with trichoscopy showing inflammatory features

Step 2: Trial conventional therapies for 6-12 months (intralesional steroids, hydroxychloroquine, finasteride)

Step 3: If progressive despite conventional therapy → Consider JAK inhibitor

Step 4: Complete baseline screening (labs, TB, hepatitis, vaccinations)

Step 5: Start with topical delgocitinib 2% cream twice daily (preferred based on RCT evidence)

Step 6: Assess response at 12 weeks clinically and by trichoscopy

Step 7: If inadequate response to topical therapy and extensive disease → Consider systemic JAK inhibitor with appropriate monitoring

Step 8: Continue therapy as long as disease remains active and treatment is tolerated

---

Note: The evidence base remains limited to one small RCT and case series 1, 2, 3. Larger randomized controlled trials are ongoing and will better define the role of JAK inhibitors in FFA 7. Current use should be considered investigational and reserved for cases where conventional therapies have failed.